An Untargeted Metabolomics Analysis of Antipsychotic Use in Bipolar Disorder
An Untargeted Metabolomics Analysis of Antipsychotic Use in Bipolar Disorder
复制标题
DOI：
10.1111/cts.12324
复制
发表时间：
2015-10-01
影响因子：
3.9
通讯作者：
Ellingrod, Vicki L.
中科院分区：
文献类型：
--
作者：
Burghardt, Kyle J.;Evans, Simon J.;Ellingrod, Vicki L.
背景第二代抗精神病药（SGA）在双相情感障碍中的应用很普遍，并在短期试验中证明有效。仍然缺乏对双相情感障碍中许多积极和消极影响的机制的理解。本研究的目的是描述与SGAs治疗的双相患者的代谢产物谱，通过比较与锂治疗的双相患者的代谢产物谱，和精神分裂症患者SGAS.MethodsCross-sectional，空腹非靶向血清代谢组学分析进行了82例诊断为双相I型障碍（n = 30 SGAs和n = 32锂）或精神分裂症（n = 20）。与SGAs治疗的双相受试者的代谢谱进行了比较，双相受试者与锂和精神分裂症受试者与SGAs治疗使用multivariate methods.ResultsPartial lease平方判别分析（PLS-DA）图显示分离与SGAs治疗的双相受试者，双相受试者与锂，或精神分裂症受试者与SGAs治疗。顶部有影响力的代谢产物的功能与几个途径，包括多不饱和脂肪酸，丙酮酸，葡萄糖，支链amino acids.ConclusionsThe研究结果，这项研究需要进一步验证，在治疗前和治疗后的双相和精神分裂症的主题，但表明，药物代谢组可能是诊断特异性的。
BackgroundSecond generation antipsychotic (SGA) use in bipolar disorder is common and has proven effective in short-term trials. There continues to be a lack of understanding of the mechanisms underlying many of their positive and negative effects in bipolar disorder. This study aimed to describe the metabolite profiles of bipolar subjects treated with SGAs by comparing to metabolite profiles of bipolar subjects treated with lithium, and schizophrenia subjects treated with SGAs.MethodsCross-sectional, fasting untargeted serum metabolomic profiling was conducted in 82 subjects diagnosed with bipolar I disorder (n = 30 on SGAs and n = 32 on lithium) or schizophrenia (n = 20). Metabolomic profiles of bipolar subjects treated with SGAs were compared to bipolar subjects treated with lithium and schizophrenia subjects treated with SGAs using multivariate methods.ResultsPartial lease square discriminant analysis (PLS-DA) plots showed separation between bipolar subjects treated with SGAs, bipolar subjects treated with lithium, or schizophrenia subjects treated with SGAs. Top influential metabolite features were associated with several pathways including that of polyunsaturated fatty acids, pyruvate, glucose, and branched chain amino acids.ConclusionsThe findings from this study require further validation in pre- and posttreated bipolar and schizophrenia subjects, but suggest that the pharmacometabolome may be diagnosis specific.